BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CCMG | CCGM - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CCMG | CCGM
X-ORIGINAL-URL:https://ccmg.51-222-78-205.ygkweb.ca
X-WR-CALDESC:Events for CCMG | CCGM
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20251005T100000
DTEND;TZID=America/Toronto:20251008T170000
DTSTAMP:20260626T132043
CREATED:20240816T180417Z
LAST-MODIFIED:20240816T180417Z
UID:10000042-1759658400-1759942800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:CAGC & CCMG Joint Annual Scientific Meeting
DESCRIPTION:Our next in-person event will be the CAGC & CCMG Joint Annual Scientific Meeting October 5-8\, 2025 at the Banff Centre for the Arts and Creativity in Banff\, Alberta. \nSave the date and more information coming soon! \nVisit the website: https://cagcccmg.com/
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/cagc-ccmg-joint-annual-scientific-meeting/
LOCATION:Banff Centre for Arts and Creativity\, Banff\, AB\, 107 Tunnel Mountain Dr\, Banff\, Alberta\, T1L 1H5\, Canada
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250926T120000
DTEND;TZID=America/Toronto:20250926T130000
DTSTAMP:20260626T132043
CREATED:20250918T224026Z
LAST-MODIFIED:20260302T214756Z
UID:10000098-1758888000-1758891600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nWe are pleased to share that as of the 2026/2027 season\, the Garrod Association will be providing two presentations per season. \nTo register\, click the button below or go to: https://us06web.zoom.us/webinar/register/WN_e2yO6xnsSK2v70BLslqwjA  \n \n  \n  \n  \n2025-2026 Leading Strand from 12:00pm – 1:00pm ET on:\nFriday September 26\, 2025 \nNeurotransmitter Disorders – Updates \nThis session will provide an introduction to monoamine and amino acid neurotransmitter disorders\, and updates on novel diagnoses and therapies. \nLearning Objectives: \n\nAssess patients presenting with symptoms of neurotransmitter disorders.\nDiagnose and treat patients with monoamine and amino acid neurotransmitter deficiencies.\n\nSpeaker: Dr. Gabriella Horvath \nBio: Dr. Gabriella Horvath is a Biochemical Geneticist\, Clinical Professor at the University of British Columbia\, Department of Pediatrics\, Division of Biochemical Genetics. She works both in the Pediatric and adult metabolic clinics\, and has special interest in neurometabolic disorders. \nFriday October 24\, 2025 \nFriday November 28\, 2025 \nFriday December 12\, 2025 at 12:30pm – 1:30pm ET\nFriday January 30\, 2026\nFriday February 27\, 2026\nFriday March 27\, 2026 \nFriday April 24\, 2026\nFriday May 29\, 2026\nFriday June 26\, 2026
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-4-2/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250627T120000
DTEND;TZID=America/Toronto:20250627T130000
DTSTAMP:20260626T132043
CREATED:20250523T151104Z
LAST-MODIFIED:20250613T163829Z
UID:10000062-1751025600-1751029200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, upcoming dates are:\nFriday June 27\, 2025 \nCatalyzing Clinical Genomic Services in British Columbia: A Collaborative Approach to Education and Implementation\nGenomics holds significant potential to enhance health outcomes\, provided that patients and healthcare providers can effectively leverage this technology. Currently\, significant barriers hinder the clinical implementation of genomics in BC\, including the lack of dedicated resources\, practice competencies and teaching time for genomic education of health professionals. \nUsing a program logic model for genomics education and evaluation\, we developed a framework with key tactics for engaging our partners in genomic education strategies for non-genetic specialists. Tailored to the BC healthcare ecosystem\, this framework guided four exemplar projects aimed at educating and enabling non-genetic specialists to improve the uptake and access of clinical genomic services in BC. \nWe will highlight successes and challenges of these projects\, with a focus on the Nurse Practitioner Education in Genomics (NP-EDGE) project\, an innovative initiative designed to support the integration of genomics into Nurse Practitioner education and practice. https://blogs.ubc.ca/npedge/ \nSpeakers: Drs. Erin DeBruin & Sarah Dewell \n \nErin DeBruin has a passion for making knowledge accessible to people in practical ways that they can actually use. As the Manager\, Professional Education and Implementation at Genome BC\, Erin focuses on connecting and amplifying stakeholders with expertise in genomics and education to increase the uptake of genomic applications. She also works with Genome BC projects to create the appropriate tools to translate their genomics projects into practice. \n  \n  \n  \n \nSarah Dewell’s research explores the development of precision health through scholarship focused on nursing education\, research\, and practice with a focus on foundational genomic knowledge for all nurses. Sarah works with an extensive network of national and international genomics nurse educators and researchers on several projects\, including the creation of a genomics educational hub (LINKAGE) and integrating genomics into the Nurse Practitioner program at TRU. Sarah is a member of the steering committees for the Global Genomics Nursing Alliance (G2NA) and the Canadian Nursing & Genomics initiative. She is also a member of the International Society of Nurses in Genetics (ISONG) and the Nursing Genomics Project Group of the National Human Genome Research Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG). \n  \n 
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/can-gard-ccmg-the-leading-strand-series-3-8/2025-06-27/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250620T110000
DTEND;TZID=America/Toronto:20250620T120000
DTSTAMP:20260626T132043
CREATED:20250613T155333Z
LAST-MODIFIED:20250613T155334Z
UID:10000069-1750417200-1750420800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, upcoming dates are:\nFriday\, June 20\, 2025\nAutoinflammatory Disorders\nThis presentation will provide an overview of the different autoinflammatory disorders\, including the monogenic forms.\n \nSpeaker: Dr. Hugo Chapdelaine \n \nDr. Hugo Chapdelaine is in charge of the Adult Clinical Immunology program at the Montreal Clinical Research Institute. He is clinical associate professor at Université de Montréal. \n 
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2-6-2/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250606T100000
DTEND;TZID=America/Toronto:20250606T140000
DTSTAMP:20260626T132043
CREATED:20250423T193510Z
LAST-MODIFIED:20250606T133634Z
UID:10000072-1749204000-1749218400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:CCMG Virtual Symposium
DESCRIPTION:This symposium will offer three different sessions to highlight expert panels with representation from Canada\, USA\, and Europe\, followed by Q&A.\nTo register for the symposium\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_Hu9KT_cbSUKg_NEvi_M4tA. \n \n  \n  \n  \n  \nThis event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists-Association canadienne des pathologistes. You may claim a maximum of 3.0 hours (credits are automatically calculated).  \nThrough an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association\, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities are eligible. \nLearning Objectives:\n1. Provide a landscape for the role that Canadian Clinical Geneticists could play in implementing therapeutics\, with national and international examples of work in progress. \n2. Explore the role that general geneticists may wish to have in this field\, working with colleagues from other branches of medicine\, and/or providing counseling and education. \n3. Set the ground for a framework on therapies in genetics through collaborations at the national and international level. \nProgram: \nPanel 1 – 10:00am – 11:00am ET\nExperts on Genetic Treatments – Brief Talks\n\nSpeakers:\n• Dr. Robert Hufnagel\n• Dr. Cam-Tu Émilie Nguyen\n• Dr. Charles Venditti\n \nThis panel will describe the speakers’ overall experience from clinical trials to clinical integration. This could include clinical trials experience\, application process to FDA/Health Canada\, approval\, post-approval experience in terms of implementation and follow-up\, with a focus on summarizing processes\, challenges\, successes\, low hanging fruits\, key players needed\, timelines. \nPanel 2 – 11:15am – 12:15pm ET\nWhat has been the experience so far\, what is our role as medical providers going forward?\nSpeakers:\n• Dr. Marc Williams\n• Dr. Saskia Koene\n• Dr. Leanne Ward \nThis panel will be based on the experience to date\, it will discuss what is realistic with regards to genetic therapies and role of geneticists\, clinical integration\, and special training. It will discuss how the integration of therapies might change the scope of practice for medical geneticists. This will focus on the challenges and opportunities\, including what diseases to focus on and whether a connection with newborn screening applies.  \nPanel 3 – 12:30pm – 2:00pm ET\nThe Interest of Canadian Geneticists on Therapies\n\nSpeakers:\n• Dr. Yannis Trakadis\n• Dr. Julie Lander Porter\n• Breanne Stewart\n• Dr. Thierry Lacaze \nThis panel will present survey results describing what medical geneticists and other specialists think about the role of medical geneticists in this area and introduce the Health Canada representative. A fellow’s experience undergoing Fellowship training in Pediatric Genomics and Gene Therapy and suggestions for optimization/future directions will be discussed.  \nMeet the Speakers\nDr. Robert Hufnagel is a physician-scientist who joined the Center for Integrated Healthcare Research in 2023. After receiving his M.D. and Ph.D. from the University of Cincinnati (Cincinnati\, Ohio)\, he completed his Pediatrics and Clinical Genetics residency at Cincinnati Children’s Hospital\, followed by fellowships in Clinical Ophthalmic Genetics at the National Eye Institute (NEI/NIH) and Clinical Molecular Genetics and Genomics at the National Human Genome Research Institute (NHGRI/NIH). \nHis research is dedicated to improving utilization of genomic data in medicine at point-of-care. Research focuses include the role of genome sequencing for rare and common diseases\, models for variant classification of pathogenicity\, and genotype-first approaches to diagnosis and management. These projects combine clinical data\, biostatistics\, and high-throughput sequencing analysis to establish patient-centered disease models for translational and preclinical studies. \nDr. Hufnagel also serves in leadership roles in several clinical and research organizations\, including the American College of Medical Genetics and Genomics (ACMG)\, the Clinical Genome Resource (ClinGen)\, the Association for Research in Vision and Ophthalmology (ARVO)\, and the Foundation Fighting Blindness (FFB). For more information on Dr. Hufnagel’s work\, please click here.  \nDr. Saskia Koene is a clinical geneticist in the Netherlands with special interest in children with neurodevelopmental disorders. As a scientist\, Dr. Koene is combining her experience during her PhD with her experience in paediatrics (2010-2018)\, clinical pharmacology and clinical genetics. Dr. Koene was in the Netherlands Medical Genetics committee that developed the statement on therapeutics and medical genetics. \n  \n \nDr. Thierry Lacaze is the RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network Nominated Principal Investigator and the Scientific Director of the Maternal Infant Child and Youth Research Network since 2018. Dr. Lacaze is a neonatologist by training and Clinical Professor of Pediatrics at the University of Calgary. \n  \n  \nDr. Cam-Tu Émilie Nguyen\, MD is a pediatric neurologist and medical director of the Neuromuscular clinic at CHU Sainte-Justine (Montreal\, QC). She is known for her innovative approaches to improving the health and quality of life of children with chronic neuromuscular conditions. Dr. Nguyen leads efforts in early detection and treatment of spinal muscular atrophy (SMA)\, having developed a treatment program that has delivered over 200 life-changing interventions for severely ill children. Dr. Nguyen has been instrumental in implementing new genetic therapies for SMA. \nIn 2023\, she was named Early Career Clinical Researcher of the Year by the Neuromuscular Disease Network for Canada. Last year\, she received the Distinction award from the Collège des Médecins du Québec in the Relève category. \n  \nDr. Julie Porter (formerly Julie Lander)  was born in Alberta\, Canada\, and grew up in Texas. She completed her PhD in Molecular and Developmental Biology at the University of Cincinnati in 2017\, and her MD also from Cincinnati in 2019. She completed a combined residency in Pediatrics and Human Genetics at Cincinnati Children’s Hospital in 2023. Following this\, she moved to Utah for fellowships in Medical Biochemical Genetics and her current fellowship in Pediatric Genomics and Gene Therapy. Julie’s career interests include the treatment of rare diseases\, particularly in the field of metabolic disorders. She is engaged in several clinical trials\, including those for gene therapy\, and is particularly interested in safe implementation of gene therapy. \n  \n  \nBreanne Stewart (BSc\, BScN\, RN) serves as the Network Director for RareKids-CAN: Pediatric Rare Disease Clinical Trials and Treatment Network- she provides strategic leadership\, oversees operations\, and drives collaboration within the network. With a focus on shaping RareKids-CAN’s direction\, Breanne is dedicated to fostering partnerships and ensuring the delivery of high-quality clinical trials and innovative research initiatives for individuals affected by rare diseases. Having joined MICYRN in 2018 as the inaugural Associate Director of Clinical Trials\, Breanne is deeply passionate about optimizing research processes in Canada to ensure timely and efficient treatment and access to therapies for patients and their families. \n  \nDr. Yannis Trakadis\, MD MSc is a medical geneticist and Associate Professor at McGill university. Dr. Trakadis serves as chair of the CCMG Metabolic Genetics Committee. His academic interests include the clinical integration of novel technologies\, targeted treatments\, and artificial intelligence (AI). Dr. Trakadis founded M.D.CyberAssistant Inc.\, demonstrating his commitment to digital health innovation to help patients and physicians. Committed to the ethical advancement of precision medicine\, Dr. Trakadis aims to improve patient care and alleviate suffering\, using AI-powered tools. \n  \n  \nDr. Charles P. Venditti\, a clinical and biochemical geneticist\, is a Senior Investigator and Chief of the Metabolic Medicine Branch in the National Human Genome Research Institute at the National Institutes of Health in Bethesda\, MD. He has developed a translational research program to study the natural history of the hereditary methylmalonic acidemias (MMA)\, cobalamin metabolic disorders\, and propionic acidemia (PA). His laboratory is developing gene\, cell and small molecules therapeutics to treat MMA and PA. \nDr. Venditti has received numerous awards\, including a Presidential Early Career Award for Scientists and Engineers\, the US Government’s highest honor for early-career scientists. He serves on numerous medical\, advisory and editorial boards\, and is a frequent ad hoc reviewer for local\, national\, and international granting agencies. He has authored more than 250 peer reviewed research articles\, reviews\, textbook chapters\, and patents. \n  \nDr. Leanne Ward is a Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa where she holds a Tier 1 Research Chair in Pediatric Bone Disorders. Dr. Ward’s research program is dedicated to the diagnosis and treatment of childhood-onset bone disorders including skeletal dysplasias\, bone fragility and mineralization disorders\, and osteoporosis due to chronic illnesses. The Ward lab has a particular focus on therapeutic trials in childhood-onset bone disorders\, emphasizing skeletal health outcomes quantified through central skeletal imaging\, and the study of novel drugs to mitigate the functional consequences of rare bone diseases. Dr. Ward is the Lead for the Innovative Therapies pillar within the Canadian Rare Disease Network (CRDN). \n  \nDr. Marc S. Williams\, MD\, FAAP\, FACMG\, FACMI is a clinical geneticist and research scientist. He is professor and director emeritus of Geisinger’s Department of Genomic Health. He is on the NHGRI Genomic Medicine working group. He was a member of the Secretary’s Advisory Committee for Genetics\, Health and Society. He served as president of the American College of Medical Genetics and Genomics. He is funded through an NHGRI genomic learning healthcare system grant. He has authored over 250 articles on a variety of topics including the economic evaluation and value of genetic services\, implementation of genomic medicine\, the use of informatics to facilitate genomic medicine and precision health\, and genomic learning health systems. \nPresenters without Conflicts of Interest\nDr. Robert Hufnagel\nDr. Saskia Koene\nDr. Julie Lander Porter\nDr. Yannis Trakadis\nDr. Marc Williams \nPresenters with Conflicts of Interest\nDr. Thierry Lacaze\nName of for-profit or not-for-profit organization(s): MICYRN\, the Maternal Infant Child and Youth Research Network\nDescription of relationship(s): Scientific Director\n \nDr. Cam-Tu Émilie Nguyen\nName of for-profit or not-for-profit organization(s): PTC \nDescription of relationship(s): Sub-investigator for a Friedreich’s Ataxia clinical trial at CHU Sainte-Justine \nBreanne Stewart\nName of for-profit or not-for-profit organization(s) : Maternal Infant Child and Youth Research Network (MICYRN)\nDescription of relationship(s) : Network Director\nName of for-profit or not-for-profit organization(s) : MICYRN/RareKids-CAN\nDescription of relationship(s) : Network Director \nDr. Charles Venditti\nName of for-profit or not-for-profit organization(s) : Addition Therapeutics\nDescription of relationship(s) : sponsored research \nDr. Leanne Ward\nName of for-profit or not-for-profit organization(s) : Ascendis\, Alexion\, QED\, Ultragenyx\, Edgewise\, Ascendis\, Roche\, and Catalyst\nDescription of relationship(s) : With funds to Dr. Ward’s institution\nName of for-profit or not-for-profit organization(s) : Amgen\, Ultragenyx\, Kyowa Kirin\, Roche\, Angitia\, Santhera\, Ipsen\, and\nCatalyst\nDescription of relationship(s) : Consultancy\, DMC or Advisory Boards\, with funds to Dr. Ward’s institution \nThank you to our Planning Committee:\nDr. Oana Caluseriu\, President\, on behalf of the Board of Directors and Dr. Yannis Trakadis\, Chair\, on behalf of the Metabolic Genetics Committee.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/ccmg-virtual-symposium-therapeutics-in-the-era-of-post-genomic-medicine-new-roles-for-the-clinical-geneticist/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250530T120000
DTEND;TZID=America/Toronto:20250530T130000
DTSTAMP:20260626T132043
CREATED:20250523T151104Z
LAST-MODIFIED:20250613T163829Z
UID:10000061-1748606400-1748610000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, upcoming dates are:\nFriday June 27\, 2025 \nCatalyzing Clinical Genomic Services in British Columbia: A Collaborative Approach to Education and Implementation\nGenomics holds significant potential to enhance health outcomes\, provided that patients and healthcare providers can effectively leverage this technology. Currently\, significant barriers hinder the clinical implementation of genomics in BC\, including the lack of dedicated resources\, practice competencies and teaching time for genomic education of health professionals. \nUsing a program logic model for genomics education and evaluation\, we developed a framework with key tactics for engaging our partners in genomic education strategies for non-genetic specialists. Tailored to the BC healthcare ecosystem\, this framework guided four exemplar projects aimed at educating and enabling non-genetic specialists to improve the uptake and access of clinical genomic services in BC. \nWe will highlight successes and challenges of these projects\, with a focus on the Nurse Practitioner Education in Genomics (NP-EDGE) project\, an innovative initiative designed to support the integration of genomics into Nurse Practitioner education and practice. https://blogs.ubc.ca/npedge/ \nSpeakers: Drs. Erin DeBruin & Sarah Dewell \n \nErin DeBruin has a passion for making knowledge accessible to people in practical ways that they can actually use. As the Manager\, Professional Education and Implementation at Genome BC\, Erin focuses on connecting and amplifying stakeholders with expertise in genomics and education to increase the uptake of genomic applications. She also works with Genome BC projects to create the appropriate tools to translate their genomics projects into practice. \n  \n  \n  \n \nSarah Dewell’s research explores the development of precision health through scholarship focused on nursing education\, research\, and practice with a focus on foundational genomic knowledge for all nurses. Sarah works with an extensive network of national and international genomics nurse educators and researchers on several projects\, including the creation of a genomics educational hub (LINKAGE) and integrating genomics into the Nurse Practitioner program at TRU. Sarah is a member of the steering committees for the Global Genomics Nursing Alliance (G2NA) and the Canadian Nursing & Genomics initiative. She is also a member of the International Society of Nurses in Genetics (ISONG) and the Nursing Genomics Project Group of the National Human Genome Research Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC-PEG). \n  \n 
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/can-gard-ccmg-the-leading-strand-series-3-8/2025-05-30/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250516T110000
DTEND;TZID=America/Toronto:20250516T120000
DTSTAMP:20260626T132043
CREATED:20250324T160701Z
LAST-MODIFIED:20250512T205359Z
UID:10000068-1747393200-1747396800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, upcoming dates are:\nFriday\, May 16\, 2025\nInherited Metabolic Disorders in Manitoba (1960-2025): Where Are We Headed?\nGlutaric aciduria type 1 (GA1) is a severe inherited neurometabolic disorder whose clinical outcome has improved after implementation of newborn screening (NBS) programs and prompt beginning of guideline-directed presymptomatic metabolic treatment. I will provide an analysis of the outcome of our 40-year experience with the diagnosis and management of GA1 which has improved but remains suboptimal. \nSpeaker: Dr. Aziz Mhanni \n \nDr. Aziz Mhanni is a Clinician Scientist in the Department of Pediatrics and Child Health\, in the Max Rady College of Medicine\, Rady Faculty of Health Sciences\, University of Manitoba\, and the Children’s Hospital Research Institute of Manitoba. He is a is a Fellow of the Royal College of Physicians of Canada\, and a Fellow of the Canadian College of Medical Genetics and Genomics. Dr. Mhanni’s clinical practice focuses on the diagnosis and management of inborn errors of metabolism (IEM). His focus in clinical research has primarily been concerned with the advances in the diagnosis and treatment of these disorders. He is heavily engaged\, both clinically and on research basis\, in advancing the care for Indigenous children and adults with metabolic disorders. He is currently serving as the President of the Canadian Association of Centers for the Management of Hereditary Metabolic Diseases (The Garrod Association).\n  \n  \nFriday\, June 20\, 2025\nMore information to come. \n 
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/telegraf-2-6/2025-05-16/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250425T120000
DTEND;TZID=America/Toronto:20250425T130000
DTSTAMP:20260626T132043
CREATED:20240917T200018Z
LAST-MODIFIED:20250416T201613Z
UID:10000060-1745582400-1745586000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, upcoming dates are:\nFriday\, April 25\, 2025 \nUnraveling the Heart: Decoding the Genetics of Congenital Heart Disease\nCongenital heart disease (CHD) is the most commonly major congenital anomaly. Genetic risk contributes to at least half of CHD\, but we have uncovered only half of the estimated 400 human CHD genes. We will review genetic causes of CHD as well as emerging evidence for influences on important health outcomes across the lifespan.\n \nSpeaker: Dr. Sarah Morton\n\n \nSarah Morton is a neonatologist and scientist at Boston Children’s Hospital. She completed her MD/PhD training at UCSF before moving to Boston. Her research group is used computational approaches to characterize the role of genetic variants in heart development and lifelong health for people with CHD. \n  \n  \nFriday\, May 30\, 2025\nMore information to come. \nFriday June 27\, 2025 \nMore information to come. \n 
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250411T110000
DTEND;TZID=America/Toronto:20250411T120000
DTSTAMP:20260626T132043
CREATED:20240917T194221Z
LAST-MODIFIED:20250324T165216Z
UID:10000052-1744369200-1744372800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, scheduled dates are: \nFriday\, April 11\, 2025\nWhat Teeth and Gums can tell us about Genetic Syndromes\nThis lecture will explore rare dental and gingival anomalies and their significance in identifying underlying systemic and genetic conditions. Dr. Kantaputra will highlight recent discoveries\, including genes linked to mesiodens and the molecular basis of the world’s smallest and largest teeth. The presentation will emphasize how oral features can offer critical clues to syndromic diagnoses and patient care. \nSpeaker: Dr. Nik Kantaputra \n \n  \nDr. Piranit Nik Kantaputra is Professor of Medical Genetics and Director of the Center of Excellence in Medical Genetics Research at Chiang Mai University\, Thailand\, where he also teaches pediatric dentistry. He has identified over 13 novel genetic syndromes—one of which bears his name—and was the first to discover the gene for isolated tongue-tie. With more than 120 publications\, his research focuses on the genetic causes of rare craniofacial and dental syndromes. \n  \n  \n  \nFriday\, May 16\, 2025\nMore information to come. \n\nFriday\, June 20\, 2025\nMore information to come.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-3/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250328T120000
DTEND;TZID=America/Toronto:20250328T130000
DTSTAMP:20260626T132043
CREATED:20250313T155149Z
LAST-MODIFIED:20250313T160155Z
UID:10000059-1743163200-1743166800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, upcoming dates are:\nFriday\, March 28\, 2025\nEmerging Sequencing Technique for Rare Neurological Diseases\nOur capacity to accurately diagnosed rare diseases\, including rare neurological diseases\, is greatly influence by the development of novel sequencing technologies. In this presentation\, Dr. Martine Tetreault will summarize the current state of the field of sequencing technologies and their application to the field of neurogenetic disease. Dr. Tetreault will focus on long-read sequencing\, and discuss its advantages and challenges.\n \nSpeaker: Dr. Martine Tetreault\n\nDr. Martine Tetreault is an Associate Professor in the Department of Neuroscience at the Université de Montréal and a researcher at the CRCHUM since 2018. Her research combines multiple omics approaches to study the genetic etiology of neuromuscular and neurodegenerative diseases. Dr. Tétreault’s career has been very productive with over 70 publications. She has received funding from several Canadian and American organizations. Recently\, she was awarded a grant from the Genome Canada Precision Health Initiative aiming at sequencing thousands of patients affected with neurological diseases using short and long-read sequencing. The quality of her research was further highlighted by receiving a FRQS Junior 2 salary award (2024)\, the David Green Rising Researcher/Clinician Award from Muscular Dystrophy Canada (2022) and the Early Career scientific award from the CRCHUM (2025). \n  \n\nFriday\, April 25\, 2025\nMore information to come. \n  \nFriday\, May 30\, 2025\nMore information to come. \n  \nFriday June 27\, 2025\nMore information to come.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-7/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250321T110000
DTEND;TZID=America/Toronto:20250321T120000
DTSTAMP:20260626T132043
CREATED:20250313T153359Z
LAST-MODIFIED:20250313T155925Z
UID:10000067-1742554800-1742558400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, upcoming dates are:\nFriday\, March 21\, 2025\nRetinal Dystrophies: Genetic Testing Approaches and Therapies\nThe clinical utility of genetic testing for inherited retinal dystrophies has dramatically altered with the advent of a clinically available gene therapy. In this presentation\, I will describe the pathophysiology and natural history of select inherited retinal dystrophy disorders\, as well as summarize a genetic testing approach and describe available and emerging therapies. \nSpeaker: Dr. Priya Bhola\nDr. Priya Bhola is a clinical geneticist at the Children’s Hospital of Eastern Ontario and an assistant professor in the Department of Pediatrics at the University of Ottawa. \n\nFriday\, April 11\, 2025\nMore information to come. \n\nFriday\, May 16\, 2025\nMore information to come. \n\nFriday\, June 20\, 2025\nMore information to come.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2-5/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250228T120000
DTEND;TZID=America/Toronto:20250228T130000
DTSTAMP:20260626T132043
CREATED:20250131T214231Z
LAST-MODIFIED:20250211T163251Z
UID:10000058-1740744000-1740747600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \nFriday February 28\, 2025\n12:00pm – 1:00pm ET \nGenome Mapping – From Development to Clinical Implementation \nOptical Genome Mapping is a non-sequencing based technology that can be used to analyze genomes for structural variation at high resolution. This technology can replace or supplement current cytogenetic techniques such as karyotype\, FISH and chromosomal microarray. The presentation will review how Optical Genome Mapping has been used to better define structural variation in hematologic malignancies in clinical samples as well as applications in pre- and post-natal cytogenetics. \nLearning Objectives: \n\nCompare the strengths and limitations of genome mapping techniques for the detection of genome wide structural variants.\nConsider the changes in clinical practice with the application of new high resolution technologies.\n\nSpeaker: Dr. Adam Smith \nBio: Dr. Smith is a dual-boarded Clinical Cytogeneticist and Clinical Molecular Geneticist certified by the Canadian College of Medical Geneticists (CCMG). Dr. Smith is also a fellow of the American College of Genetics and Genomics (FACMG) and a Certified Laboratory Geneticist (erCLG) by the European Board of Medical Genetics. \nDr. Smith completed his Master’s degree and Ph.D. at the University of Toronto. Dr. Smith is currently a Clinical Laboratory Director at Labcorp. He is also an internationally recognized leader in the implementation of Optical Genome Mapping in a clinical setting. Dr. Smith received the CCMG Genetics and Genomics Award for Innovation (2024) for his work in Optical Genome Mapping.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-6/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250221T110000
DTEND;TZID=America/Toronto:20250221T120000
DTSTAMP:20260626T132043
CREATED:20250130T194944Z
LAST-MODIFIED:20250211T164310Z
UID:10000066-1740135600-1740139200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \nFriday\, February 21\, 2025\n11:00am – 12:00pm ET \nPediatric Onset Cancer Predisposition Syndromes: Screening and Diagnosis \nThis presentation will include a brief description of the epidemiological and clinical aspects of cancer predisposition syndromes (CPSs)\, from a practical pediatric oncology perspective. Approaches to screening and diagnosis of CPSs in children with cancer\, including the MIPOGG app\, will be presented and compared. \nLearning Objectives: \n\nIdentify the main cancer predisposition syndromes in the pediatric oncology population.\nUnderstand and compare the main approaches to CPS screening and diagnosis in children with cancer.\nDescribe the eHealth MIPOGG app and its utilities in pediatric oncology.\n\n \n  \nSpeaker: Dr. Catherine Goudie \nBio: Dr. Catherine Goudie is a pediatric hematologist-oncologist and clinician-scientist working at the Montreal Children’s Hospital/McGill University Health Centre since 2018. Dr. Goudie completed a fellowship in cancer predisposition syndromes and\, recently\, a Masters in Ethics focusing on the challenges of genomic information sharing. Her clinical and research programs focus on screening approaches for cancer predisposition syndromes and cancer surveillance in children and young adults. 
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2-4/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250131T120000
DTEND;TZID=America/Toronto:20250131T130000
DTSTAMP:20260626T132043
CREATED:20250114T170054Z
LAST-MODIFIED:20250114T170143Z
UID:10000057-1738324800-1738328400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, scheduled dates are: \nFriday September 27\, 2024 \nFriday October 25\, 2024 \nFriday November 22\, 2024 \nFriday December 13\, 2024 – cancelled \nFriday\, January 31\, 2025 \nLiver-Directed Gene Therapy for Inherited Metabolic Disorders \nLearning objectives: \n\nQuote the most commonly used vectors for liver-directed gene therapy.\nAssess the safety and efficacy of gene therapy\, especially for inherited metabolic diseases.\nUnderstand the current limitations and issues of liver-directed gene therapy.\n\nDescription of talk: \nInherited metabolic diseases (IMD) are disorders affecting human biochemical pathways and represent attractive targets for gene therapy because of their severity\, high overall prevalence\, lack of effective treatments\, and possibility of early diagnosis through newborn screening. The liver is a central organ involved in several metabolic reactions and is a favorite target for gene therapy in many IMD. Adeno-associated virus (AAV) vectors have emerged in the last years as the preferred vectors for in vivo gene delivery. Gene replacement strategies are aimed either at correcting liver disease or providing a source for production and secretion of the lacking enzyme for cross-correction of other tissues. A number of preclinical studies have been conducted in the last two decades and\, for several diseases\, gene therapy has reached the clinical stage. In my talk\, our experience on two ongoing clinical gene therapy trials for IMD and I will highlight current obstacles and future strategies to overcome them. \nSpeaker: Dr. Nicola Brunetti \nBio: \nNicola Brunetti-Pierri graduated in Medicine and trained in Pediatrics at University of Naples Federico II. He then moved to Baylor College of Medicine\, Houston\, TX for a post-doctoral fellowship and clinical training in Medical Genetics and Biochemical Genetics. He was assistant professor in the Department of Molecular and Human Genetics of Baylor College of Medicine until he returned to Italy. As a physician-scientist his research goals are to elucidate the pathogenetic mechanisms and develop effective therapies for genetic diseases. He identified several new genetic diseases and generated proof-of-concept studies for new therapies in genetic disorders. He received awards from ASGCT and ESGCT and fundings by NIH and ERC. He is the principal investigator of phase 1/2 gene therapy clinical trials. He is Professor of Pediatrics at Federico II University of Naples\, Principal Investigator at the Telethon Institute of Genetics and Medicine (TIGEM)\, Italy. \nFriday February 28\, 2025 \nFriday\, March 28\, 2025 \nFriday\, April 25\, 2025 \nFriday\, May 30\, 2025 \nFriday June 27\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-5/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250124T120000
DTEND;TZID=America/Toronto:20250124T130000
DTSTAMP:20260626T132043
CREATED:20250106T174829Z
LAST-MODIFIED:20250106T174829Z
UID:10000071-1737720000-1737723600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:CCMG Webinar – Presented by Illumina
DESCRIPTION:Collaboration between Industry\, Societies and other Stakeholders to Increase Access to Genetic Services \nAt the end of this session\, participants will be able to:\n• identify a few collaborations between industry and medical societies and the outcomes of these;\n• describe the benefits of working with diverse stakeholders; and\n• propose ideas for potential collaboration with industry or other organizations. \nSpeaker: Melissa Dempsey \nBio \nMelissa began her career as a clinical and lab genetic counselor at the University of Chicago. She then moved to her hometown in Indiana\, where she built a Genetic Counseling Clinic for both oncology and cardiology patients. Melissa’s desire for a larger impact moved her to industry\, as she worked to expand genomic services through marketing at two major diagnostic laboratories. She also led the Global Customer Success Team for Face2Gene software\, an AI platform that aids clinicians in diagnosing children with rare genetic diseases via facial recognition. \nWorking in Market Development for Illumina\, Melissa seeks creative ways to increase access to genetic testing through larger projects and thoughtful collaborations. She loves building relationships with experts and sharing her vision for routine genomic testing as an integral part of medical care.
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/ccmg-webinar-presented-by-illumina-2/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250117T123000
DTEND;TZID=America/Toronto:20250117T133000
DTSTAMP:20260626T132043
CREATED:20240917T193028Z
LAST-MODIFIED:20250613T155412Z
UID:10000070-1737117000-1737120600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, upcoming dates are:\nFriday\, June 20\, 2025\nAutoinflammatory Disorders\nThis presentation will provide an overview of the different autoinflammatory disorders\, including the monogenic forms.\n \nSpeaker: Dr. Hugo Chapdelaine \n \nDr. Hugo Chapdelaine is in charge of the Adult Clinical Immunology program at the Montreal Clinical Research Institute. He is clinical associate professor at Université de Montréal.
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/telegraf-2/2025-01-17/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250117T110000
DTEND;TZID=America/Toronto:20250117T120000
DTSTAMP:20260626T132043
CREATED:20250106T174236Z
LAST-MODIFIED:20250109T191750Z
UID:10000065-1737111600-1737115200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, scheduled dates are: \nFriday\, October 18\, 2024 \nFriday\, November 15\, 2024 – to be rescheduled \nFriday\, December 20\, 2024 \nFriday\, January 17\, 2025 \nThere will be 2 TeleGraf presentations on January 17th. \n11:00-12:00 – Alkaptonuria: Review of Its Chronic And (rare) Acute Complications \nAlkaptonuria was one of Garrod’s original four inborn errors of metabolism. Chronic complications of the condition are well\nrecognized and there is some evidence to inform management approaches. However\, acute complications of Alkaptonuria are\nrare and poorly recognized. In this presentation I will review Alkaptonuria with a focus on rare acute presentations of the\ndisease. \nSpeaker: Dr. Chris Smith \nBio \nDr. Chris Smith was born and raised in Calgary\, Alberta\, where he undertook the majority of his training and presently resides.\nHe earned a Bachelor of Health Sciences from the University of Calgary before matriculating to the Cumming School of\nMedicine Leaders in Medicine Program\, graduating from the combined MD/MSc program in 2019. He completed a 5-year Royal\nCollege Residency in Medical Genetics & Genomics at the Alberta Children’s Hospital. Now in his first year of practice Dr. Smith\npractices in pediatric and prenatal genetics while training part time in clinical biochemical genetics. \n12:30-1:30 – The Launch of the Silent Genomes Indigenous Background Variant Library: Building the Path to Genetic and Genomic Equity for Indigenous Patients. \nAt the end of this session\, participants will be able to: \n\nidentify three contributors to health disparity for genetic diagnosis and genetic health care in Canada.\ncite the Global Indigenous Data Alliance Care Principles for upholding Indigenous Rights and Interests in the context of genomic data.\nhave the tools to access the Silent Genomes Project Indigenous background variant library to obtain variant frequency information for their Indigenous patients.\n\nSpeaker: Dr. Laura Arbour \nBio \nDr. Laura Arbour. MSc\, MSc\, MD\, FRCPC\, FCCMG is a Professor in the Department of Medical Genetics at the University of British Columbia situated at the Island Medical Program in Victoria BC where she is also a clinician. Trained as both pediatrician and clinical geneticist\, she has been addressing the genetic determinants of health with Indigenous populations for more than three decades. Through her UBC Community Genetics Research Program she has focused on rare\, single gene disorders and complex conditions in partnership with First Nations of BC and Inuit of Nunavut. Her research has been continuously funded since 2004 through such funders as the Canadian Institutes of Health Research\, Genome Canada\, Genome BC including the recent Silent Genomes Project (2018-2024)\, co-led by Dr’s Wyeth Wasserman and Nadine Caron addressing inequity in genomic diagnosis for Indigenous patients of Canada. \nFriday\, February 21\, 2025 \nFriday\, March 21\, 2025 \nFriday\, April 11\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2-3/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241220T110000
DTEND;TZID=America/Toronto:20241220T120000
DTSTAMP:20260626T132043
CREATED:20240917T193028Z
LAST-MODIFIED:20250613T155412Z
UID:10000064-1734692400-1734696000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, upcoming dates are:\nFriday\, June 20\, 2025\nAutoinflammatory Disorders\nThis presentation will provide an overview of the different autoinflammatory disorders\, including the monogenic forms.\n \nSpeaker: Dr. Hugo Chapdelaine \n \nDr. Hugo Chapdelaine is in charge of the Adult Clinical Immunology program at the Montreal Clinical Research Institute. He is clinical associate professor at Université de Montréal.
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/telegraf-2/2024-12-20/
CATEGORIES:TeleGraf
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241122T110000
DTEND;TZID=America/Toronto:20241122T120000
DTSTAMP:20260626T132043
CREATED:20241118T172844Z
LAST-MODIFIED:20241118T172845Z
UID:10000063-1732273200-1732276800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \nMitochondrial Dynamics and Genetic Neuropathy \nThe presentation will introduce the concept of mitochondrial dynamics and examine how impaired mitochondrial dynamics contributes to genetic neuropathy. Specific emphasis will be placed on CMT2A and pathogenic variants in MFN2\, how these variants impact MFN2 functions\, and additional pathogenic phenotypes associated with certain MFN2 variants. \nLearning Objectives: \n\nUnderstand the concept of mitochondrial dynamics and how impairment leads to disease.\nDescribe the functions performed by MFN2.\nRecognize that MFN2 variants may impact different MFN2 functions leading to phenotypic variability in CMT2A.\n\nDr. Timothy Shutt \nDr. Timothy Shutt is an Associate Professor in the Departments of Medical Genetics and Biochemistry & Molecular Biology at the University of Calgary. He obtained his PhD in Biochemistry and Molecular Biology at Dalhousie University\, and carried-out post doctoral fellowships at Yale University and the University of Ottawa Heart Institute. \nDr. Shutt’s current research focuses on human mitochondria\, essential organelles best known for generating both energy and reactive oxygen species (ROS). However\, mitochondria are also key regulators of many other important cellular functions\, and their dysfunction is implicated in a broad spectrum of human disorders and aging. Dr. Shutt’s research interests comprise two key aspects of mitochondrial function\, mitochondrial dynamics and mitochondrial DNA (mtDNA). \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, scheduled dates are: \nFriday September 27\, 2024 \nFriday October 25\, 2024 \nFriday November 22\, 2024 \nFriday December 13\, 2024 \nFriday\, January 31\, 2025 \nFriday February 28\, 2025 \nFriday\, March 28\, 2025 \nFriday\, April 25\, 2025 \nFriday\, May 30\, 2025 \nFriday June 27\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-4/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241025T120000
DTEND;TZID=America/Toronto:20241025T130000
DTSTAMP:20260626T132043
CREATED:20241024T145345Z
LAST-MODIFIED:20241024T145346Z
UID:10000054-1729857600-1729861200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nThe Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, scheduled dates are: \nFriday September 27\, 2024 \nFriday October 25\, 2024 \nPsychiatric Phenotyping and Precision Prescribing for Rare Genetic Conditions \nThis presentation will begin by describing the high rate and heterogeneous presentations of neuropsychiatric disorders in rare genetic conditions. Current research efforts to improve psychiatric phenotyping across the lifespan in rare genetic conditions will be discussed. The contemporary use of language and diagnostic terms with respect to neurodevelopmental and neuropsychiatric disorders will be summarized. The limited evidence to inform prescribing practices for behavioural and psychiatric disorders in rare genetic conditions will then be reviewed. \nLearning objectives: \n\nDescribe the high rate and heterogeneous presentations of neuropsychiatric disorders in rare and ultra rare genetic conditions.\nUnderstand current research efforts to improve psychiatric phenotyping across the lifespan in rare genetic conditions.\nAppreciate the limited evidence to inform prescribing practices for behavioural and psychiatric disorders in rare genetic conditions.\n\nSpeaker: Dr\, Danielle Baribeau \nDr. Danielle Baribeau is a child and adolescent psychiatrist and clinician-scientist at Holland Bloorview Kids Rehabilitation Hospital in Toronto. Her clinical focus is in autism\, rare genetic neurodevelopmental disorders\, and psychopharmacology. She is also the lead of the Ontario Provincial Genetics Program Expert Group for genetic testing in neurodevelopmental disorders. Her CIHR funded research program is focused on clinically translating genetic advances into improved mental health care in autism and neurodevelopmental disorders. Her current studies use health administrative data to examine health system outcomes in autism and rare genetic diseases from across Ontario. She is the site- or principal investigator for several clinical trials of medications for behavioural and mental health outcomes in autism. \nFriday November 22\, 2024 \nFriday December 13\, 2024 \nFriday\, January 31\, 2025 \nFriday February 28\, 2025 \nFriday\, March 28\, 2025 \nFriday\, April 25\, 2025 \nFriday\, May 30\, 2025 \nFriday June 27\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-3/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20241018T110000
DTEND;TZID=America/Toronto:20241018T120000
DTSTAMP:20260626T132043
CREATED:20241017T133247Z
LAST-MODIFIED:20241017T133311Z
UID:10000043-1729249200-1729252800@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_7trryYsQRROjpvFp0VoSHw.  \n \n  \n  \n  \n  \n2024-2025 TeleGraf from 11:00am – 12:00pm ET\, scheduled dates are: \nFriday\, October 18\, 2024 \nTitle: 2SLGBTQI Issues in Medical Genetics Practice \nWe will provide a talk on the provision of equitable health care to individuals within the 2SLGBTQI community with an emphasis on medical genetics. We will define the 2SLGBTQI acronym\, examine challenges and barriers faced by 2SLGBTQI individuals in the community and in health care settings\, demonstrate correct pedigree nomenclature for gender diverse individuals\, and explore case examples specific to the practice of medical genetics. \nSpeakers: \nD’Arcy Prendergast \nD’Arcy Prendergast is a medical genetics and genomics trainee at the University of Toronto currently completing additional subspecialization in prenatal genetics and the care of patients with variations of sexual characteristics. He has given variations of this talk on 2SLGBTQI care with genetic counseling colleagues Ronni Teitelbaum and Carleigh Robertson since 2021 to a variety of MD and GC audiences and is pleased to be able to present this to the TeleGraf audience. \nDr. Prendergast graduated from the Schulich School of Medicine’s Windsor Campus in 2019 and has since been a resident physician in the Medical Genetics and Genomics Residency program at the University of Toronto. His academic interests include the role of geneticists in the care of gender-diverse patients\, the intersection of palliative care and clinical genetics\, and in broader equity and inclusion efforts within the field of genetics. \nDr. Carleigh Robertson \nCarleigh Robertson is a genetic counsellor at the Fred A. Litwin Family Centre in Genetic Medicine at University Health Network\, and an instructor in the MSc Genetic Counselling program within the Temerty Faculty of Medicine at the University of Toronto. She graduated in 2014 from the University of Guelph with a BSc in Molecular Biology and Psychology\, then completed her Master’s of Science in Genetic Counselling at McGill University in 2016. Before relocating to Toronto in 2018\, she provided general genetic counselling services at Health Sciences North in Sudbury\, Ontario and participated in teaching and clinical supervision for trainees at the Northern Ontario School of Medicine. Her research has explored the experiences of transgender individuals in genetic counselling settings and strategies for enhancing medical genetics care for the 2SLGBTQI community. She is certified by the American Board of Genetic Counseling (ABGC). \nDr. Ronni Teitelbaum \nRonni Teitelbaum\, MSc\, CGC\, CCGC received a Master of Science degree in Genetic Counselling from the University of British Columbia in 2002. In 2002\, she was certified in Genetic Counselling by the American Board of Genetic Counseling (ABGC) and the Canadian Association of Genetic Counsellors (CAGC). She is a member of both the ABGC and the CAGC. She is a lecturer and provides clinical supervision to students in the Master of Science degree in Genetic Counselling at the University of Toronto. Ronni has over 20 years of genetic counselling experience in the public healthcare sector in Ontario. She is currently employed as a Genetic Counsellor at Medcan. \nFriday\, November 15\, 2024 \nFriday\, December 20\, 2024 \nFriday\, January 17\, 2025 \nFriday\, February 21\, 2025 \nFriday\, March 21\, 2025 \nFriday\, April 11\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2-2/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240927T120000
DTEND;TZID=America/Toronto:20240927T130000
DTSTAMP:20260626T132043
CREATED:20240923T165618Z
LAST-MODIFIED:20240923T165634Z
UID:10000053-1727438400-1727442000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nTo register\, click the button below or go to https://us06web.zoom.us/webinar/register/WN_MzE5qgCSQCyPI-X9Ys7_IQ  \n \n  \n  \n  \n  \n2024-2025 Leading Strand from 12:00pm – 1:00pm ET\, scheduled dates are: \nFriday September 27\, 2024\nTitle: Standardizing Genome Editing for Rare Disease\nLearning objectives: \n\nIdentify editing strategies for rare diseases.\nDistinguish editing platforms.\n\nSpeaker: Dr. Mark Osborn \nBio: Dr. Mark Osborn is an Associate Professor at the University of Minnesota\, Department of Pediatrics. Dr. Osborn works at the Division of Blood and Marrow Transplant & Cellular & Gene Therapy Center for Genome Engineering. \n  \nFriday October 25\, 2024 \nFriday November 22\, 2024 \nFriday December 13\, 2024 \nFriday\, January 31\, 2025 \nFriday February 28\, 2025 \nFriday\, March 28\, 2025 \nFriday\, April 25\, 2025 \nFriday\, May 30\, 2025 \nFriday June 27\, 2025 \nFriday\, May 16\, 2025 \nFriday\, June 20\, 2025
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-3-2/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240628T120000
DTEND;TZID=America/Toronto:20240628T130000
DTSTAMP:20260626T132043
CREATED:20230927T144256Z
LAST-MODIFIED:20240626T165750Z
UID:10000040-1719576000-1719579600@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nAdvancing Clinical Genetics Education in Canada: Current Practices and Emerging Needs \nSpeaker: Dr. Hanna Faghfoury \nBio \nDr. Hanna Faghfoury is a clinical and metabolic geneticist at Mount Sinai Hospital and University Health Network in Toronto as well as an Associate Professor and clinician teacher at the University of Toronto. She has led numerous roles within undergraduate and postgraduate genetics education at Sickkids and at the University of Toronto\, and currently directs the Medical Genetics and Genomics residency program and the Canadian College of Medical Geneticist (CCMG) fellowship programs in both Clinical genetics and Biochemical genetics. Most recently\, she was appointed Expert lead in Inherited Metabolic Disorders at Ontario Health where her team aims to enhance access to care for patients and families with inherited metabolic conditions.  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-06-28/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240621T110000
DTEND;TZID=America/Toronto:20240621T120000
DTSTAMP:20260626T132043
CREATED:20230927T144938Z
LAST-MODIFIED:20240617T190848Z
UID:10000024-1718967600-1718971200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \n \n  \n  \nBeyond Diagnostic Yield: Clinical and Ethical Implications of Implementation of Genomic Technologies in Practice \nThis presentation will discuss a range of clinical and ethical implications of the implementation of genomic technologies in practice\, beyond its demonstrated improvement of diagnostic yield. \nLearning objectives: \n\nIdentify clinical and ethical issues raised by genomic sequencing.\nDescribe the concept of clinical utility and how it is used to assess genomic sequencing.\nRecognize the dual role of clinicians involved in genomic sequencing and its implications for patient care.\nReflect on the implications of secondary findings in practice\, in particular their actionability in children.\nConsider patient/parent expectations about genomic sequencing.\n\nSpeaker:\nDr. Anne-Marie Laberge \nBio \nDr. Laberge is a Medical Geneticist and Head of the Division of Medical Genetics at CHU Ste-Justine\, Clinical Full Professor in the Department of Pediatrics\, Faculty of Medicine\, and Department of Social and Preventive Medicine at the School of Public Health at Université de Montréal. Dr Laberge completed a residency in Medical Genetics at Université de Montréal\, an MPH and a PhD in Public Health Genetics\, both at the University of Washington. Dr Laberge was president of the Quebec Medical Geneticists Association for 5 years and is currently Chair of the Quebec Advisory Committee on Newborn Screening\, of the Quebec Molecular Diagnosis Network Incidental Findings Working Group and of the newly formed Quebec Central Ethics Committee on Medically Assisted Reproduction. Dr Laberge’s research focuses on the utility of genetic tests in practice and how genetic information influences patient management and patient/families’ decision-making. \nFriday\, October 20\, 2023\nFriday\, November 17\, 2023\nFriday\, December 15\, 2023\nFriday\, January 19\, 2024\nFriday\, February 16\, 2024\nFriday\, March 15\, 2024\nFriday\, April 19\, 2024\nFriday\, May 17\, 2024\nFriday\, June 21\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2024-06-21/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240531T120000
DTEND;TZID=America/Toronto:20240531T130000
DTSTAMP:20260626T132043
CREATED:20230927T144256Z
LAST-MODIFIED:20240527T133756Z
UID:10000039-1717156800-1717160400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nTitle: Development of Gene Therapy for GM2 Gangliosidosis and Creatine Deficiency Disorders \nIt is all about developing gene therapies for genetic conditions. \nLearning objectives: \n\nDefine ‘Gene Therapy’.\nList at least three factors affecting gene therapy outcomes.\nList at least three conditions that can be treated by gene therapy- approved products.\nList at least three ethical issues with gene therapy.\n\n \n  \nSpeaker: Dr. Jagdeep Walia \nBio \nDr. Jagdeep Walia is a medical geneticist and full-time professor in the Division of Medical Genetics\, Department of Pediatrics. A medical school graduate from India\, he finished his residency in Medical Genetics from University of Manitoba and then joined Queen’s University in 2012 as a clinical Geneticist. \nDr. Walia’s research lab focuses on developing novel gene therapy approaches for inherited and acquired neurodegenerative disorders. His focus is on GM2 gangliosidoses\, creatine deficiency disorders\, galactosemia and 2 rare autism spectrum disorders. The translational nature of this work is exemplified by the initiation of a phase 1/2 clinical trial for infantile GM2 gangliosidoses at Queen’s University/Kingston Health Sciences Centre using adeno-associated virus vector (AAV) as a tool for gene transfer to the central and peripheral nervous system. He has published more than 50 peer-reviewed articles and has been invited as a speaker on the topic of gene therapy for local\, national and international conferences. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-05-24/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240517T110000
DTEND;TZID=America/Toronto:20240517T120000
DTSTAMP:20260626T132043
CREATED:20230927T144938Z
LAST-MODIFIED:20240415T151742Z
UID:10000025-1715943600-1715947200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \n \n  \n  \nFriday\, October 20\, 2023\nFriday\, November 17\, 2023\nFriday\, December 15\, 2023\nFriday\, January 19\, 2024\nFriday\, February 16\, 2024\nFriday\, March 15\, 2024\nFriday\, April 19\, 2024\nFriday\, May 17\, 2024\nFriday\, June 21\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/%tribe_events_slug%/telegraf-2024-05-17/2024-05-17/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240426T120000
DTEND;TZID=America/Toronto:20240426T130000
DTSTAMP:20260626T132043
CREATED:20240425T172107Z
LAST-MODIFIED:20240425T172804Z
UID:10000022-1714132800-1714136400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \nThe Cardiac Genome Clinic: Using the Genome to Enhance Care for Patients and Families with Heart Disease \nAn overview of the Ted Rogers Cardiac Genome Clinic’s activities in providing personalized care for patients with congenital heart disease\, cardiomyopathy\, arrhythmia\, and aortopathies. \nLearning objectives: \n\nUnderstand the current yield and utility of short-read WGS in congenital heart disease (CHD).\nLearn how NOTCH1 diagnosis is changing the care of CHD.\nHighlight EIF3 as an example of gene discovery in CHD.\n\nSpeaker – Dr. Rebekah Jobling  \nDr. Jobling completed her medical training at the University of Calgary. She completed both her residency in Medical Genetics and Genomics and her Canadian College of Medical Genetics training in Molecular Laboratory genetics at the Hospital for Sick Children. Currently she works as a Clinical and Laboratory geneticist at SickKids. She has been a Principal Investigator in the Ted Rogers Cardiac Genome Clinic since 2018. \n  \n \n  \n  \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240419T110000
DTEND;TZID=America/Toronto:20240419T120000
DTSTAMP:20260626T132043
CREATED:20230927T144938Z
LAST-MODIFIED:20240415T185514Z
UID:10000026-1713524400-1713528000@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \n \n  \n  \nConsiderations for Developing\, Testing\, and Administering Genetic Therapies \nGenetic therapies like gene replacement therapy and antisense oligonucleotides (ASOs) are increasingly asked about in the clinic by patients and families. We will review specific examples of commercially available and bespoke/precision/”n-of-1″ treatments\, and discuss considerations related to the design\, testing\, and implementation of genetic therapies for rare genetic diseases. \nLearning objectives: \n\nIdentify approved genetic therapies for rare genetic diseases.\nCompare different strategies for DNA and RNA based treatments.\nDescribe considerations that are relevant to patient and family counselling.\n\nSpeaker:\nDr. Gregory Costain \nBio\nGreg Costain is a medical geneticist and physician-scientist at SickKids\, and co-leads the Advanced Therapeutics Node of the SickKids Precision Child Health initiative. \n  \nFriday\, October 20\, 2023\nFriday\, November 17\, 2023\nFriday\, December 15\, 2023\nFriday\, January 19\, 2024\nFriday\, February 16\, 2024\nFriday\, March 15\, 2024\nFriday\, April 19\, 2024\nFriday\, May 17\, 2024\nFriday\, June 21\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2024-04-19/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240328T110000
DTEND;TZID=America/Toronto:20240328T120000
DTSTAMP:20260626T132043
CREATED:20230927T144938Z
LAST-MODIFIED:20240325T200300Z
UID:10000027-1711623600-1711627200@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:TeleGraf
DESCRIPTION:About this series – Telehealth for Genetics Residents and Fellows. A monthly teaching session brought to you by the members of the RCPSC Specialty Committee in Medical Genetics. \n \n  \n  \nInclusion of Molecular Genetics in Newborn Screening \nThis presentation will provide a quick review of NBS in Ontario and where molecular genetics is being used. The goal is to understand some of the techniques and logistics associated with molecular genetic in NBS at present\, and to examine some of the opportunities and challenges associated with molecular genetics in NBS. \nLearning objectives: \n– Examine some of the opportunities and challenges associated with molecular genetics in NBS.\n– Understand some of the techniques and logistics associated with molecular genetic in NBS at present. \nSpeaker: \nDr. Kristin Kernohan \nKristin Kernohan\, Laboratory Head of Molecular Genetics Laboratory\, completed her HB.Sc\, Honours specialization in Genetics and Ph.D in Biochemistry at the University of Western Ontario. After graduate school she completed a post-doctoral fellowship with Care4Rare and CCMG training at the Children’s Hospital of Eastern Ontario before joining NSO in 2018. Dr. Kernohan is certified by the Canadian College of Medical Geneticists. Her research interests include the identification of new disease genes and developmental of new technologies for molecular diagnostics. \n  \nFriday\, October 20\, 2023\nFriday\, November 17\, 2023\nFriday\, December 15\, 2023\nFriday\, January 19\, 2024\nFriday\, February 16\, 2024\nFriday\, March 28\, 2024\nFriday\, April 19\, 2024\nFriday\, May 17\, 2024\nFriday\, June 21\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/telegraf-2024-03-15/
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240322T120000
DTEND;TZID=America/Toronto:20240322T130000
DTSTAMP:20260626T132043
CREATED:20230927T144256Z
LAST-MODIFIED:20240402T175721Z
UID:10000038-1711108800-1711112400@ccmg.51-222-78-205.ygkweb.ca
SUMMARY:Can-GARD/CCMG – The Leading Strand Series
DESCRIPTION:This series is for genetics health professionals led by the Canadian College of Medical Genetics and co-sponsored by Can-GARD. Speakers will be translation-focused researchers\, clinicians and innovators.  The series will help attendees anticipate\, access\, and apply new approaches and technologies for patient care. \nNew \nAs of March 2024\, the Can-GARD/CCMG Leading Strand Series is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. \nNote\, to obtain credit for this CPD activity\, you must keep track of the seminars attended.  An easy way to do this is to download and save the certificate for each seminar attended which is available through the evaluation link sent after the seminar to attendees.  A letter at the end of the year will NOT be sent. \n \n  \n  \nGenetic Medicine For Rare Neurogenetic Disease \nIn this presentation\, I will summarize the current state of the field of genetic medicine approaches for neurogenetic disease. I will focus on gene therapy\, and talk about its advantages and challenges. \nLearning objectives: \n\nIdentify the benefits and challenges of gene therapy for neurogenetic disease.\nAssess the emerging genetic medicine approaches for treating neurogenetic conditions.\n\nSpeaker:\nDr. Jim Dowling \nBio \nDr. Jim Dowling is a staff clinician and senior scientist at the Hospital for Sick Children and a Professor of Paediatrics and Molecular Genetics at the University of Toronto. He is also the Mogford Campbell Family Chair of Paediatric Neuroscience. Dr. Dowling received his BSc and MSc from Yale University\, his MD/PhD from the University of Chicago\, and did his residency in child neurology at Children’s Hospital of Philadelphia. \nDr. Dowling’s clinical expertise is in childhood neurogenetic disorders. His research examines questions of disease pathogenesis and therapy development for congenital muscle diseases. In addition to his research program\, he currently serves as board chair of TREAT NMD\, as an executive board member of the World Muscle Society\, and as the pediatric lead of the NMD4C pan-Canadian neuromuscular network. He was recently honored to receive the Researcher of the Year Award from Muscular Dystrophy Canada. \nFriday\, September 29\, 2023\nFriday\, October 27\, 2023 – cancelled\nFriday\, November 24\, 2023\nFriday\, December 15\, 2023 @ 12:30pm – 1:30pm ET\nFriday\, January 26\, 2024\nFriday\, February 23\, 2024\nFriday\, March 22\, 2024\nFriday\, April 26\, 2024\nFriday\, May 31\, 2024\nFriday\, June 28\, 2024
URL:https://ccmg.51-222-78-205.ygkweb.ca/event/can-gard-ccmg-the-leading-strand-series-2024-03-22/
CATEGORIES:Leading Strand
ORGANIZER;CN="CCMG | CCGM":MAILTO:info@ccmg-ccgm.org
END:VEVENT
END:VCALENDAR